Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma

作者：Hoi Yan Ng, Josephine Mun Yee Ko, Ka On Lam, Dora L.�W. Kwong, Anthony W.I. Lo, Yhi Wong, Claudia Lai Yin Wong, Siu Yin Chan, Kwan Kit Chan, Tsz Ting Law, Wei Dai, Henry Chun Hung Fong, Faith Sin Fai Choy, Chun Kit Lo, Cancan Chen, Simon Ying Kit Law, Maria Li Lung · 发表于：JAMA Surgery · 年份：2023 · DOI：10.1001/jamasurg.2023.4395 · 被引用次数：46 · 研究领域：Cancer Genomics and Diagnostics、Cancer Cells and Metastasis、Esophageal Cancer Research and Treatment

Importance: Esophageal squamous cell carcinoma (ESCC) is a deadly disease with frequent recurrence. There are unmet needs for prognostic biomarkers for dynamically monitoring disease progression and detecting minimal residual disease. Objective: To examine whether circulating tumor DNA is clinically useful as a prognostic biomarker for ESCC recurrence and patient survival. Design, Setting, and Participants: This single-center, population-based cohort study consecutively enrolled 147 patients receiving curative (n = 74) or palliative (n = 73) treatment at the surgery and clinical oncology departments of Queen Mary Hospital in Hong Kong from August 1, 2016, to September 31, 2021. Patients were followed up for 2 years. Plasma samples were collected at different longitudinal time points for a prospective circulating tumor DNA (ctDNA) next-generation sequencing profiling study of 77 actionable genes. Intervention: Patients were treated with up-front surgery, neoadjuvant chemoradiotherapy plus surgery with or without adjuvant therapy, or palliative chemotherapy (CT). Main Outcomes and Measures: Detection of circulating tumor DNA (ctDNA), progression-free survival (PFS), and overall survival (OS). Results: A total of 478 serial plasma samples from 147 patients with locoregional or metastatic ESCC were prospectively analyzed. Among the 74 patients in the curative group (median [range] age, 66 [46-85] years; 56 [76.0%] male), 44 (59.5%) relapsed and 36 (48.6%) died. For patients recei...